ACCRELIST LTD (QZG) Fair Value & Analysis
Healthcare · SG · Market cap 20.9M SGD
Fair value as of: Aug 13, 2026
From 8 valuation models · updated 4 days ago
Share price +11.3% over the past month.
A solid business, but screening 48% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (0.0360 SGD). The favourable scenario is already priced in.
- Solid but not exceptional quality (51/100) and above fair value, neither a clear bargain nor a standout compounder.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.
How to read this chart
60‑month range 0.0290 SGD – 0.0830 SGD · fair‑value band 0.0299 SGD – 0.0360 SGD · the 0.0690 SGD price screens above the 0.0360 SGD fair value. Dashed = 300-day average. As of Aug 13, 2026.
Analysis
ACCRELIST LTD (QZG) currently trades at 0.0690 SGD, while our model-based Fair Value estimate is 0.0360 SGD, implying the stock looks roughly 47.8% overvalued today. The Quality Score stands at 51/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: medium).
Over the trailing twelve months, ACCRELIST LTD generated revenue of 15.6M SGD at a net margin of -1.7%. Revenue grew 27.8% year over year. It earns a return on equity of -10.4%. Net debt stands at 3.6M SGD. Fundamentals as of Aug 13, 2026
Our scenario range runs from 0.0299 SGD (bear case) to 0.0360 SGD (bull case); at 0.0690 SGD, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 1% below its 52-week high and 130% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -14% fair-value upside, at -48%, QZG screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 8 models by family
Widest divergence: Multiples (0.0200 SGD) versus DCF Models (0.0100 SGD). Highest evidence: Growth DCF (80).
Notify me when QZG reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 50 · Market factors (momentum, volatility) 82
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Accrelist Ltd., an investment holding company, engages in the medical aesthetics business in Singapore, Malaysia, and Indonesia. It operates through three segments: Mechanical Business Unit (MBU), Aesthetic Medical Services (AMS), and Others segment.
Full company description
Accrelist Ltd., an investment holding company, engages in the medical aesthetics business in Singapore, Malaysia, and Indonesia. It operates through three segments: Mechanical Business Unit (MBU), Aesthetic Medical Services (AMS), and Others segment. The MBU segment offers mould design and fabrication services for consumer electronics, household appliances, automotive, and computer peripherals, as well as precision plastic injection moulding services for customers' finished products. Its AMS segment offers aesthetic services and solutions, including cosmetic dermatology and skin laser services. The company is also involved in the operation of aesthetic medical clinics; retail sale of pharmaceutical and medical goods; and development and distribution of original design manufacturer (ODM) clinical skincare products and other non-ODM products. The company was formerly known as WE Holdings Ltd. and changed its name to Accrelist Ltd. in November 2016. Accrelist Ltd. was founded in 1986 and is headquartered in Singapore.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
ACCRELIST LTD reported revenue of 15.6M SGD in FY2026 versus 241M SGD in FY2022, a compound −49.5%/yr. Reported net income was −264K SGD in FY2026.
QZG screens 48% overvalued. Compare with HCA Healthcare, Inc →
Peer Group
Medical Care Facilities · 267 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Care Facilities median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| HCA Healthcare, Inc HCA | $414.59 | $547.67 | +32% |
| Fresenius SE FRE | €46.82 | €32.15 | -31% |
| Dr. Sulaiman Al Habib Medical Services Group 4013 | 235.00 SAR | 112.37 SAR | -52% |
| IHH Healthcare Berhad, an investment holding company, Q0F | 2.67 SGD | 1.44 SGD | -46% |
| Tenet Healthcare Corporation THC | $266.79 | $330.25 | +24% |
| Rede D'Or São Luiz S.A RDOR3 | R$33.97 | R$47.31 | +39% |
| Apollo Hospitals Enterprise Limited APOLLOHOSP | ₹8,565 | ₹2,955 | -65% |
| Aier Eye Hospital Group 300015 | ¥8.87 | ¥7.67 | -14% |
| Max Healthcare Institute Limited MAXHEALTH | ₹1,008 | ₹284.87 | -72% |
| Bangkok Dusit Medical Services Public Company BDMS | 19.70 THB | 18.57 THB | -6% |
Compare ACCRELIST LTD with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is ACCRELIST LTD (QZG) overvalued or undervalued?
What is the fair value of QZG?
What is the quality score of QZG?
What is the revenue of ACCRELIST LTD (QZG)?
What is the net profit margin of QZG?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track ACCRELIST LTD and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.